Top 15 companies to work for in Singapore in 2024

Top 15 companies to work for in Singapore in 2024

These are the top companies to work for in Singapore in 2024, according to LinkedIn. Carlina Teteris | Moment | Getty Images Banks dominated the top 5 best companies in Singapore to work for, according to LinkedIn’s list on the best workplaces in the country in 2024. “Commercial banking firms from banking to insurance and … Read more

Stocks give up gains, but busy earnings week is good news for investors

Stocks give up gains, but busy earnings week is good news for investors

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) Markets wobbly: After a weak attempt … Read more

Amazon and Dell are benefiting the most from Nvidia partnership

Amazon and Dell are benefiting the most from Nvidia partnership

Recently, I read a terrific little book about Abraham Lincoln, called “Lincoln Reconsidered,” by Professor David Herbert Donald, and the fundamental premise behind the title was simple: If you want to go down in history as a politician who is compassionate, honest and a visionary, you have to get right with Lincoln. That’s how sainted … Read more

AI catalysts ahead that could boost Alphabet and Apple — and 3 quick stock takes

AI catalysts ahead that could boost Alphabet and Apple — and 3 quick stock takes

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) Taking a breather: Stocks were mixed … Read more

We’re buying more of this health-care company amid an overdone sell-off

We’re buying more of this health-care company amid an overdone sell-off

Shortly after the opening bell, we will be buying 140 shares of Abbott Laboratories at roughly $112. Following the trade, Jim Cramer’s Charitable Trust will own 700 shares of ABT, increasing our weighting in the portfolio to 2.42% from 1.95%. We are buying more Abbott Laboratories into its recent weakness as we continue to believe … Read more

Nvidia stomps the bears. Jim Cramer on struggling stocks Starbucks, Abbott

Nvidia stomps the bears. Jim Cramer on struggling stocks Starbucks, Abbott

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) Markets rebound as Nvidia goes green: … Read more

We’re looking to buy more of this health care stock after a big selloff

We’re looking to buy more of this health care stock after a big selloff

Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. U.S. stocks were mixed Tuesday as Big Tech names dragged down the S & P 500 and Nasdaq. The Dow was up after the opening. The rally in Nvidia cooled … Read more

Investing Club’s Q4 2023 Earnings Report Card

Investing Club’s Q4 2023 Earnings Report Card

The fourth quarter was pretty darn good for our stocks. Results were mostly better than expected, and many corporate leaders forecasted more of the same. For good reason: Businesses are starting to spend again, supply chain conditions continue to improve and the consumer remains resilient. Roughly 73% of companies in the S & P 500 … Read more

It’s not too late to buy Abbott stock after Friday selloff

It’s not too late to buy Abbott stock after Friday selloff

Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. U.S. stocks jumped Monday as the Nasdaq and S & P 500 attempts to recover from back-to-back weekly losses. Major gains were seen in tech stocks to start the new … Read more

Here is Eli Lilly’s competitive edge in GLP-1 obesity drugs and Abbott’s secondary play

Here is Eli Lilly’s competitive edge in GLP-1 obesity drugs and Abbott’s secondary play

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.) Inflation relief: The stock market was … Read more